CFDE Data Portal | Search RNASEH1-DT

	Label	Description
	RNASEH1-DT Gene (Entity type)	ENSG00000234171 - RNASEH1 divergent transcript
	GSE226249 pirfenidone HL 2 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE135350 2 V 4 DEXAMETHASONE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE195663 cisplatin 0 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE146358 dopamine 3 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE168745 H-7 JHH-7 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE212330 azacitidine 1 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE129542 BAT1 knockdown RNA Small Interfering 0 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE169617 azacitidine 1 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE196343 metformin 1 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS

RNASEH1-DT

ENSG00000234171 - RNASEH1 divergent transcript

GSE226249 pirfenidone HL 2 v 1 human up

A Gene Set from LINCS

GSE135350 2 V 4 DEXAMETHASONE HUMAN DN

A Gene Set from LINCS

GSE195663 cisplatin 0 v 3 human up

A Gene Set from LINCS

GSE146358 dopamine 3 v 7 human dn

A Gene Set from LINCS

GSE168745 H-7 JHH-7 0 v 1 human dn

A Gene Set from LINCS

GSE212330 azacitidine 1 v 0 human dn

A Gene Set from LINCS

GSE129542 BAT1 knockdown RNA Small Interfering 0 v 2 human up

A Gene Set from LINCS

GSE169617 azacitidine 1 v 2 human up

A Gene Set from LINCS

GSE196343 metformin 1 v 0 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.